Literature DB >> 31637202

Effects of 0.4% ripasudil hydrochloride hydrate on morphological changes in rabbit eyes.

Bundit Limratchatamorn1,2, Ken Asakawa3, Kimiyo Mashimo2, Shigekazu Uga2, Hitoshi Ishikawa2,3.   

Abstract

We evaluated the cellular structure changes after continuous use of ripasudil hydrochloride hydrate in rabbit eyes which might affect its own efficacy and adverse effects. Two pigmented Dutch rabbits and 1 Japanese white rabbit were instilled with 0.4% ripasudil hydrochloride hydrate to the left eye twice daily. The right eye was observed as the control. Both eyes of all 3 rabbits were then enucleated for histopathologic examination by light and electron microscope at 1mo in 1 of the pigmented Dutch rabbits, 3mo in the other pigmented Dutch rabbit, and in the Japanese white rabbit after instillation. Microscopic observations showed increase intercellular space in trabecular meshwork, ciliary body, and iris stoma, increase pigmented granule number and size in iris epithelial cells, and decrease actin filament in iris muscle fiber cells. Consequently, ripasudil hydrochloride hydrate decreases the intraocular pressure by improving the conventional outflow and may also facilitate the unconventional outflow via intercellular space widening without serious side effects. International Journal of Ophthalmology Press.

Entities:  

Keywords:  actin filament; rabbit; ripasudil hydrochloride hydrate; side effect

Year:  2019        PMID: 31637202      PMCID: PMC6796090          DOI: 10.18240/ijo.2019.10.18

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  20 in total

1.  Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.

Authors:  Kenji Inoue; Ryoko Okayama; Minako Shiokawa; Kyoko Ishida; Goji Tomita
Journal:  Int Ophthalmol       Date:  2017-01-06       Impact factor: 2.031

Review 2.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

3.  The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma.

Authors:  Kotaro Yamamoto; Kazuichi Maruyama; Noriko Himori; Kazuko Omodaka; Yu Yokoyama; Yukihiro Shiga; Ryu Morin; Toru Nakazawa
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-02       Impact factor: 4.799

4.  Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes.

Authors:  Emi Nakajima; Takeshi Nakajima; Yoko Minagawa; Thomas R Shearer; Mitsuyoshi Azuma
Journal:  J Pharm Sci       Date:  2005-04       Impact factor: 3.534

5.  Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.

Authors:  Hiroshi Inazaki; Satoshi Kobayashi; Yoko Anzai; Hisayoshi Satoh; Shimpei Sato; Maiko Inoue; Shin Yamane; Kazuaki Kadonosono
Journal:  J Glaucoma       Date:  2017-02       Impact factor: 2.503

Review 6.  Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

Authors:  Toshihiro Inoue; Hidenobu Tanihara
Journal:  Expert Opin Pharmacother       Date:  2017-09-14       Impact factor: 3.889

7.  Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery.

Authors:  Megumi Honjo; Hidenobu Tanihara; Takanori Kameda; Takahiro Kawaji; Nagahisa Yoshimura; Makoto Araie
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-12       Impact factor: 4.799

8.  Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.

Authors:  Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Makoto Araie
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

9.  Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.

Authors:  Yoshio Kaneko; Masayuki Ohta; Toshihiro Inoue; Ken Mizuno; Tomoyuki Isobe; Sohei Tanabe; Hidenobu Tanihara
Journal:  Sci Rep       Date:  2016-01-19       Impact factor: 4.379

Review 10.  An emerging treatment option for glaucoma: Rho kinase inhibitors.

Authors:  Sean K Wang; Robert T Chang
Journal:  Clin Ophthalmol       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.